Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms

AIDS

Volumn 24, Issue 13, 2010, Pages 2130-2133

  Melica, Giovanna ^a   Canestri, Ana ^b   Peytavin, Gilles ^c   Lelievre, Jean D ^a   Bouvier Alias, Magali ^a   Clavel, Cyril ^b   Calvez, Vincent ^b   Lascaux, Anne S ^a   Katlama, Christine ^b   Levy, Yves ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR PLUS RITONAVIR; FOSCARNET SODIUM; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; ZIDOVUDINE;

ADULT; ARTICLE; BRAIN LYMPHOMA; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG BLOOD LEVEL; DRUG RESPONSE; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TRIAZOLES;

EID: 77955416696     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833c9353     Document Type: Article

References (17)

1. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992; 42:1736-1739.
2. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197 (Suppl 3): S294-S306.
3. Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998; 12:389-394.
4. Brew BJ, Rosenblum M, Cronin K, Price RW. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 1995; 38:563-570.
5. Wiley CA, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol 1994; 36:673-676.
6. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
7. Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalo-pathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003; 17:1897-1906.
8. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-4732.
9. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 2005; 191:890-898.
10. Soulie C, Tubiana R, Simon A, Lambert-Niclot S, Malet I, Canestri A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr 2009; 51:60-64.
11. Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351:1547-1551.
12. Burger DM, Kraaijeveld CL, Meenhorst PL, Mulder JW, Koks CH, Bult A, Beijnen JH. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7:1581-1587.
13. Min SS, Corbett AH, Rezk N,Cu-Uvin S, Fiscus SA, Petch L, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004; 37:1577-1580.
14. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre and postexposure prophylaxis. AIDS 2007; 21:1899-1907.
15. Yilmaz A, Watson V, Else L, Gisslen M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009; 23:2537-2540.
16. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84:75-82.
17. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, et al. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 2009; 32:1588-1593.